This committee is responsible for developing trials that include agents that target specific biologic pathways, and in particular, developing strategies, trials, and programs that transect the classic disease-oriented approach. The committee coordinates its scientific development with the 11 disease-oriented scientific committees and working groups in the Therapeutic Studies Program. With expertise in the early clinical development of novel targeted therapies, the Developmental Therapeutics Committee and its expanded membership are in a unique position to facilitate the creation of a new stratum of trials. At least 1 representative from each disease-oriented committee or working group is appointed as a member. Like the Laboratory Science and Pathology Committee, it also seeks experts in genetic, RNA, miRNA and protein-based assay development, regardless of their institution’s membership status in the Group.
Keith T. Flaherty, MD
Massachusetts General Hospital Cancer Center
|Cancer Control and Outcomes Program|
|Therapeutic Studies Program|
|Biomarker Sciences Program|